Heart Rhythm Management Centre, UZ Brussel-VUB, Brussels, Belgium.
Heart Rhythm Management Centre, UZ Brussel-VUB, Brussels, Belgium.
Heart Rhythm. 2015 Jul;12(7):1476-82. doi: 10.1016/j.hrthm.2015.04.001. Epub 2015 Apr 3.
The second-generation cryoballoon Advance (CB-A) recently launched on the market has technical modifications designed to significantly improve procedural outcome with respect to the first-generation device.
The purpose of this study was to evaluate the overall incidence of complications in a large sample of patients having undergone pulmonary vein (PV) isolation with CB-A technology.
All consecutive patients who underwent PV isolation procedures using CB-A technology between June 2012 and February 2015 were considered. Exclusion criteria were presence of an intracavitary thrombus, uncontrolled heart failure, moderate or severe valvular disease, left atrial diameter ≥55 mm, and contraindications to general anesthesia.
During the study period, 500 consecutive patients (67% male, age 57.6 ± 12.9 years) were enrolled. Major complications occurred in 10 patients (2.0%): vascular complications at the puncture site in 6 (1.2%), and thromboembolic events, cardiac tamponade, persisting phrenic nerve palsy, and retroperitoneal hematoma all occurred in a single patient respectively (0.2%). Phrenic nerve palsy occurred in 36 patients (7.2%) and did not revert in only 1 patient at final follow-up of 20 months. No deaths related to the procedure occurred. No predictors of major complication were found.
The present findings highlight that PV isolation using CB-A technology can be safely performed with a low incidence of adverse events. The incidence of major complications after atrial fibrillation ablation procedures using CB-A technology was 2% in our study. The most frequent complication consisted of vascular complications at the puncture site. No deaths related to the procedure occurred.
第二代冷冻球囊消融仪 Advance(CB-A)最近上市,其设计进行了技术改良,旨在相较于第一代设备显著改善手术结果。
本研究旨在评估使用 CB-A 技术行肺静脉(PV)隔离术的大量患者总体并发症发生率。
所有于 2012 年 6 月至 2015 年 2 月期间因行 PV 隔离术而使用 CB-A 技术的连续患者均被纳入研究。排除标准为存在心腔内血栓、未控制的心力衰竭、中度或重度瓣膜疾病、左心房直径≥55mm 以及全麻禁忌证。
在研究期间,共纳入 500 例连续患者(67%为男性,年龄 57.6±12.9 岁)。10 例患者(2.0%)发生了主要并发症:穿刺部位血管并发症 6 例(1.2%),血栓栓塞事件、心脏压塞、持续性膈神经麻痹和腹膜后血肿各 1 例(0.2%)。膈神经麻痹发生于 36 例患者(7.2%),20 个月最终随访时仅 1 例未恢复。无与手术相关的死亡病例。未发现主要并发症的预测因素。
本研究结果表明,使用 CB-A 技术行 PV 隔离术安全可行,不良事件发生率低。本研究中使用 CB-A 技术行房颤消融术的主要并发症发生率为 2%。最常见的并发症为穿刺部位的血管并发症。无与手术相关的死亡病例。